
Approval has been granted by the Azerbaijani authorities for a trial to proceed testing the combined use of the Sputnik V vaccine and AstraZeneca’s (LSE: AZN) jab to protect against COVID-19.
Previously, Moscow’s Gamaleya National Center, where Sputnik V was developed, along with the Russian Direct Investment Fund (RDIF), AstraZeneca and R-Pharm, signed an agreement to cooperate on COVID-19 vaccine development, which was announced in December 2020 in the presence of President Vladimir Putin.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze